SCHEMBL5872768

SCHEMBL5872768

Cc1cc(I)ccc1Nc1c(C(=O)O)cc(C(=O)NCc2ccncc2)c(F)c1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SORT1 Q99523 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
AURKA O14965 3/20 0.45
TNFRSF1A P19438 3/20 0.45
KDR P35968 2/20 0.45
MAP3K9 P80192 2/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPK1 P28482 2/20 0.45
IDO1 P14902 3/20 0.43
MAP2K1 Q02750 4/20 0.43
MAP2K2 P36507 2/20 0.43
HSD17B10 Q99714 1/20 0.42
SRC P12931 2/20 0.42
PRKCB P05771 1/20 0.42
STK3 Q13188 1/20 0.42
HTT P42858 1/20 0.42
GAA P10253 1/20 0.41
ABL1 P00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872838 0.89 USP2 (0.50) SORT1SMN1; SMN2MEN1KMT2ATDP1
SCHEMBL6035831 0.86 KMT2A (0.47) SORT1SMN1; SMN2AURKATNFRSF1AKDR
SCHEMBL6035660 0.86 MAP2K1 (0.56) SORT1SMN1; SMN2MEN1KMT2ATDP1
SCHEMBL5872840 0.85 USP2 (0.50) SORT1SMN1; SMN2MEN1KMT2ATDP1
SCHEMBL5872858 0.83 MAP2K1 (0.51) SMN1; SMN2AURKATNFRSF1AKDRMAP3K9
SCHEMBL5872850 0.82 MAP2K1 (0.56) SMN1; SMN2AURKATNFRSF1AKDRMAP3K9
SCHEMBL6035690 0.81 SMN1; SMN2 (0.50) SORT1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL6035398 0.80 SMN1; SMN2 (0.49) SORT1SMN1; SMN2MEN1KMT2AMAPK1
SCHEMBL5872861 0.79 MEN1 (0.53) SMN1; SMN2AURKATNFRSF1AKDRMAP3K9
SCHEMBL5872815 0.79 SMN1; SMN2 (0.44) SORT1SMN1; SMN2MEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 SORT1 4712/4885SMN1; SMN2 3308/4885AURKA 2531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.